Amplia Therapeutics Reports Strong Clinical Data, Expands Trials and Strengthens IP
Event summary
- ACCENT trial shows 35% objective response rate for narmafotinib with gemcitabine and Abraxane®, surpassing the 23% benchmark for chemotherapy alone.
- AMPLICITY trial initiated, combining narmafotinib with FOLFIRINOX chemotherapy, with patient recruitment ongoing in Australia and US sites planned.
- Key patent for narmafotinib granted, extending protection to at least 2040 in the US and other jurisdictions.
- Amplia uplisted to the OTCQB Venture Market, enhancing investor reach in the US.
- Cash position of $31.5 million as of December 2025, with $2.4 million net operating cash inflows during the quarter.
The big picture
Amplia Therapeutics is making significant strides in the development of narmafotinib, its FAK inhibitor, with promising clinical data and strategic regulatory and commercial advancements. The company's focus on pancreatic cancer, a high-unmet-need indication, positions it within a competitive but growing segment of the oncology market. The uplisting to the OTCQB Venture Market and the granting of key patents further strengthen its position as it seeks to attract more investors and partners.
What we're watching
- Clinical Efficacy
- Whether the ACCENT trial's 35% objective response rate can be sustained and translated into longer-term survival benefits.
- Regulatory Pathway
- The pace at which the AMPLICITY trial progresses and the impact of FDA feedback on dose optimization strategy.
- Financial Sustainability
- How Amplia manages its cash position and operating costs as it advances multiple clinical trials.
Related topics